KROATIEN! 2PERLEN !!!!! - 500 Beiträge pro Seite

[igor1]

gehe stichwort PLIVA

[igor1]

Kroatien news leider nur unter http://www.bluebull.com/HR/en/main.html

[igor1]

einschaetzung zu Pliva 899878?

[Computeraktie]

wäre nett wenn du ne kurze info abgeben würdest. was ist es für ein unternehmen, wie kommst du darauf usw.usw.usw.

[igor1]

Leider habe Ich Schwerichkeiten mit Deutsche Grammatik aber gehe zu STICHWORT :PLIVA es sind genug infos vorhanden!Es ist alltes board!
Pliva im moment einstieg kurse!

[igor1]

Meine einschetzung 20% in 6 monate!

[igor1]

Produktpalete:
ANDOL® (acetylsalicylic acid)
ANDOL® 100 (acetylsalicylic acid)
ANDOL® C (acetylsalicylic acid, comb. excl.
psycholeptics)
ARTROCAM® (tenoxicam)
BETRION® (mupirocin)
CILAZIL® (cilazapril)
DIKLONAT® (diclofenac)
GASTAL® (aluminium hydroxide - magnesium carbon
gel + magnesium hidroxide)
GEOKORTON® (hydrocortisone and antibiotics &
hydrocortisone and antiinfectives)
GEONISTIN® (nystatin)
HEPTANON® (methadone)
HIPERDON®RETARD (oxprenolol and other diuretics)
HOMOFAN® cartridge 100 (highly purified human
insulin)
HOMOLONG® (highly purified human insulin)
HOMORAP® cartridge 100 (highly purified human
insulin)
IZOSAN® (troclosen - sodium)
KETOCEF® (cefuroxime)
KLAVOCIN® (amoxicillin and enzyme inhibitor)
MIROCEF® (cefazidime)
NOVOCEF® (cefuroxime)
OIKAMID® (piracetam)
PEPTORAN® (ranitidine)
PHEMITON® (methylphenobarbital)
PLIBEX® (vitamin B-komplex)
PLIVADIAL® (hemofiltrate)
PLIVADON® (paracetamol, combinations)
PLIVASEPT® foaming (klorheksidin)
PLIVIT® C (ascorbic acid (vit C))
SINERSUL® (sulfametrole and trimethoprim)
SUMAMED® (azithromycin)
SUPREMIN® (butamirate)
TINIDIL® (isosorbide dinitrate)
TONOCARDIN® (doxazosin)
ULZOL® (omeprazole)
AVIOMARIN® (dimenhydrinate)
DIASPAM® (aspartam)
ENERBOL® (pyritinol)
FLEGAMINA® (bromhexine)
HEPATIL® (ornithine aspartate)
LECITAN® (lecithin)
SADAMIN® (xantinol nicotinate)
VENOTREX® (troxerutin)
MUKOLINA® (carbocisteine)
Enalapril Lachema® (enalapril)
Leucovorin Ca Lachema® (calcium folinate)
Dacarbazin Lachema® (dacarbazine)
Tamoxifen Lachema® (tamoxifen)
Methotrexat Lachema® (mitoxantrone)

FINE CHEMICALS

Products:

Azithromycin
Acetozolamide
Chlorthalidone
Hydrochlorothiazide
Ketoprofen
Sulfamethoxazole
Sulfisoxazole Acetyl
Other bulk pharmaceuticals for human and veterinary
use
Intermediaries and general use chemical products

ANIMAL HEALTH AND AGROCHEMICALS

Products:

AMPIVET® (ampicillin)
AY - PEST®
AY - VAK BARTHA®
BENZAPEN® (penicillin)
BRODILON® (bromadiolone)
BRONHIKAL®
BRONHOPEST®
DAVAK®
ERY - OL®
ERY - VAK®
FACIRON® (chlorophacinone)
GEOMYCIN® (oxytetracyline)
GEOTILIN® (oxytetracycline, tiamulin)
GUMBOKAL®
GUMPESKAL®
KOSTOVIT® (vitamins, minerals)
MONIL® (albendazole)
NEOCIKLIN® (oxytrtracycline, neomycin)
NEOPITROID® (permethrine)
NUTRICIN® (oxytrtracycline, neomycin, sulfadimidine,
sulfaguanidine)
PESTIKAL®
PLIVACOR® (dexamethasone)
PLIVAK®
RABIKAL®
SIMIVET® (amoxicilin)
SUSTREPEN® (penicillin, dihydrostreptomycin)
TIAVET® (tiamulin)
TRIMETOSUL® (sulfonamide, trimethoprim)
TUBERITE® (cipc)
VETOFLOK® (enrofloxacin)

FOODS

Products:

BEBIMIL®
BEBIPAPA®
CEDEVITA®
CEDEVITA SPORT®
DIABIT®
HOPA YUMMY®
KVIK®
LAKTOVIT®
MINI CEDEVITA®
MINI PEPERMINT®
PEPERMINT®
PEPERMINT® classic
PROBAVIN®
REHIDROMIKS®
RONDO C®
RONDSEPT®
SOYAMIL®
TRENDY®
UVIN H CAJ®
VAU-VAU®
VIVERA®
VIVOPAN®
KVASAC®
ZRNOPAN®
HEMIN C®
ASKOPAN®
NEGROPAN®
PECIPAN®
SANOPAN®
AMIPAN®
EXTRAPAN®

COSMETICS AND PERSONAL HYGIENE

Products:

ASEBON®
ASEPSOLETE®
ASEPSOL AEROSOL®
DIPTEROL® (deet)
GMIZIN® (permethrine, bioaletrin)
MOLIN® (permethrine)
NEOPITROID® (permethrine, d-phenothrine)
PLIDENTA®
RALON®
ROSAL® (ROSAL CLEAR FACE)
SIMBI®
SUMIFEN®
WC FRESH®

[igor1]

von Alec 15.02.00 10:17:40
betrifft Aktie: PLIVA DD GDR S 20/KK 100 469309
Habe heute gekauft nachdem ich den Wert seit November in meiner Watchlist hatte. Hatte damals einen Bericht auf CNN gesehen der mich neugierig gemacht hat. Weiss jemand was ueber den aktuellen Stand der Entwicklung der Antibiotika gegen multiresistente Staph. aureus. Das wurde in dem Bericht als Zugpferd von Pliva herausgestellt. Bin selber Arzt und kenne das Problem mit diesen Intensiv-Keimen. Sollte sich da tatsaechlich was tun gibts fuer den Kurs kein halten. Allerdings wird weltweit nach entsprechenden Antibiotika geforscht. Angeblich sei man damals aber bereits in fortgeschrittenen Testphasen gewesen. Wenn jemand was weiss bin ich fuer jede Meldung dankbar. Infos zu diesem Wert sind etwas schwer zu bekommen.
gruss

[zwrecht]

erstaunlich, wo du überall auftauchst !
Nun aber gute Nacht !
------
Die vorhergesagten Orkanböen sind immer noch nicht da.

[igor1]

Founded in 1921, PLIVA is today the largest pharmaceutical company in Croatia and by sales, the largest in Central and Eastern Europe. Since April 1996, PLIVA’s shares have been listed on the London Stock Exchange, a first for a Central and Eastern European manufacturing company.

Healthcare is central to PLIVA and the company produces a wide range of quality pharmaceutical, animal health and agrochemical products. PLIVA also produces a range of food and beverage items and a line of cosmetics and personal hygiene products.

PLIVA’s best selling product is its patented oral antibiotic, azithromycin, which PLIVA markets in Central and Eastern Europe under the brand name Sumamed. PLIVA’s azithromycin has also been licensed to Pfizer, marketed as Zithromax in the United States and elsewhere. PLIVA also produces and markets drugs under license from a number of multinational pharmaceutical companies.

PLIVA is proud of its Research and Development. Current research and development programs are working on new chemical entities yielding anti-infective and anti-inflammatory products with development activities in the fields of chemical synthesis and technology, biotechnology and drug development. Here at PLIVA, it is our belief that solid research and development combined with the ability to react to the demands of the healthcare market will ensure the continued growth and success of the company.

[igor1]

PLIVA Receives a License from BAYER AG for a New Chemical Entity for the Treatment of Fungal Infections

PLIVA d.d. (`PLIVA`) announced today that it has received a license for a new chemical entity for the treatment of fungal infections from BAYER AG, Germany, a compound in its final stage of pre-clinical trials.

The compound BAY 10-8888, part of the family of beta-amino acids, was identified at Bayer during an effort to find novel treatment options for fungal infections caused by the Candida yeast. Candida infections are prevalent in patients suffering from AIDS or those undergoing cancer chemotherapy and/or immunosuppressive therapy treatment e.g. for organ transplantation and vaginal mycosis. Furthermore, Candida has been identified as the fourth most common pathogen in nosocomial infections in hospitalized patients.

The total market size for anti-fungals amounted to USD 2.6 billion in 1999. Only the azole compound class, which was developed in the early 80s and now dominates over 60% of the market, is currently available for oral treatment of the aforementioned diseases,. Due to the increasing prevalence of Candida infections and the frequent use of azoles in treatment, however, severe resistance problems have arisen in recent years.

The compound BAY 10-8888 displays high activity both in vitro and in vivo against Candida infections. Due to its novel mode of action, the compound additionally combats azole resistant pathogens. According to the data generated in various species, the compound exerts highly favorable pharmacokinetic behavior, indicating a single daily dose for patients. The compound would be the first novel class for the oral treatment of yeast infections following the introduction of azoles in the 70s.

Due to a shift in its business strategy, BAYER decided to leave the anti-fungal segment and make the compound available for licensing. In its licensing agreement with BAYER, PLIVA received worldwide development and marketing rights to the product under non-disclosed terms.

"PLIVA continues to undertake strong steps in an effort to further expand its position in the anti-infective business area," comments Mr. Radan Spaventi, Chief Scientific Officer of PLIVA. "In addition to our successful in-house research efforts in anti-bacterials, BAY 10-8888 will allow us to further broaden our product portfolio in anti-infectives. We believe that this product will represent a significant contribution to the anti-fungal market, given its activity against strains resistant to existing drugs."

PLIVA has renamed the compound PLD-118, according to its classification scheme, and plans to start clinical development this year. In line with its R&D strategy, PLIVA intends to establish a relationship with a global partner for the development and marketing of the product after completion of Phase I and/or Phase II clinical trials. PLIVA`s total R&D expenditures in 2000 are expected to reach about HRK 330 million.

For further information, please contact:

Erika Kaspar
Vice President, Communications and Corporate Affairs
Tel: [phone]
Fax: [phone]
E-mail: [e-mail]
Marija Mandic
Financial Analyst
Tel: [phone]
Fax: [phone]
E-mail: [e-mail]

[igor1]

From PLIVA’s President

Welcome to PLIVA! Here at PLIVA, we have been manufacturing pharmaceuticals for over three quarters of a century. Over the last sixty years, we have been working continuously toward the discovery and development of new entities and products. It is with this tradition firmly in mind that we are now preparing to enter the new millennium.

Much has changed over the last decade, not only here at PLIVA but throughout Europe and the world. Ten years ago, PLIVA was a state-owned company with an excellent reputation in drug research, becoming well-known after the discovery of what is now the best selling macrolide antibiotic in the world, azithromycin. Now, we are a joint stock company with significant international investment and involvement, and our shares are now listed on the London Stock Exchange. We have acquired a majority stake in one of Poland’s largest drug producers and are continuing our investment in the markets of Central and Eastern Europe. PLIVA is now the leading pharmaceuticals company in this region. We are indeed proud of our accomplishments thus far, but we have no intention of resting on our laurels.

In the time ahead, PLIVA will continue to grow, developing and consolidating its leading position. As with any serious drug maker, research and development activities are central, and PLIVA will continue its investment in R & D, not only in the areas of pure and developmental research but also in technological improvements. We will continue our cooperation with other large pharmaceutical companies, Pfizer and Warner-Lambert to name just two, and continue our expansion internationally.

Through these activities, we are convinced that we will not only continue our success as a company, but also continue to find cures and lessen the suffering of people worldwide.

Zeljko Covic, President

[igor1]

FINANCIAL OVERVIEW
REVENUES
REVENUE BY MARKET
OPERATING COSTS
PROFITABILITY
FINANCIAL POSITION
FINANCIAL POLICIES 1996-1999
INVESTMENTS
REVENUES

Revenue by Business Segment. In 1999 PLIVA achieved positive operating results, continuing its growth trend over the last few years. PLIVA Group revenues totalled HRK 4,180.5 m., an increase of 16.9% over 1998, despite a multitude of unfavourable conditions in Croatia and its surrounding region. Reaching a total of HRK 945.5 m., royalties represented the largest rate of revenue growth at 66.9%.
PLIVA Group sales amounted to HRK 3,156.6 m., 7.2 % over previous year levels, resulting predominantly from the 46.2%, or HRK 226 m., sales increase recorded by Fine Chemicals.
Pharmaceuticals and Cosmetics and Personal Hygiene sales remained virtually unchanged, while Foodstuffs and Animal Health and Agrochemicals experienced a slight decline.
During 1999, 66% of PLIVA Group revenues were achieved on international markets, exposing the Group to respective exchange rate fluctuations. Over the period, the HRK depreciated 7.1% against the EURO and EURO currencies, and 11.8% against the USD. Nevertheless, over the same period the HRK appreciated 1.7% against the PLN. Overall, the impact of foreign exchange fluctuations was positive, increasing revenues by 5.6% (HRK 233 m.), due to a strengthening of the HRK over the remaining currencies that contributed to PLIVA`s revenues.
The most significant increase in share of sales by a business segment was attained by the Fine Chemicals segment, growing from 16.6% in 1998 to 22.7% in 1999. The Pharmaceuticals segment held the majority stake in sales with a 58.1% share.

Pharmaceuticals. Total pharmaceutical sales amounted to HRK 1,834.5 m., a 0.7% increase over 1998.
Croatian sales alone yielded HRK 943.5 m., a 0.7% increase over the previous year. New and innovative products, introduced throughout the year, stimulated a 5% growth in sales volume, accounting for 12.5% of the total value of pharmaceuticals sales. Offsetting the price decline on the Croatian market with new product launches, PLIVA was able to achieve the strategic goal of maintaining its leading position on the Croatian market.
International pharmaceutical sales totalled HRK 891.0 m., exceeding last year`s levels by 0.7%. This slight growth resulted from a decline in Slovenian sales (due to price reductions), the loss of licensed products in Poland, as well as lower sales in China (47% decline) and the CIS region (12% decline).
Poland represented Pharmaceuticals` second largest market with sales of HRK 492 m., a 5% increase over the preceding year.
In Slovenia, PLIVA has successfully retained its leading position among foreign companies despite the new price-reference system that has reduced the price of its drugs on the Slovenian market.
Russian sales strongly recovered by year-end after an initial sales decline in the first half of the year. Thanks to a near threefold sales increase in the second half of the year, sales in Russia reached HRK 65.6 m., representing a 13% decrease throughout the entire year.
PLIVA is the best performing pharmaceutical company in B&H, second only to Bosnalijek. Increased sales of all its leading finished products contributed to a 21% sales increase in 1999.
With a growth of 30%, PLIVA recorded an excellent level of sales in Macedonia despite an ageing product assortment, the war in neighbouring Yugoslavia, problems in healthcare financing and price dumping by generic competitors.
Sales in the Czech Republic amounted to HRK 26.8 m., a 9% fall from 1998. This decline was the result of a recession and high price pressures, which together led to a contraction of the antibiotic market.
Sumamed (azithromycin, antiBIOTIC) with sales of HRK 254.7 m. retained its leading
position among pharmaceutical products with an overall growth of 3.4%, resulting from its achievements on international markets. PLIVA Krakow`s leading product, Vitaminum C
(asorbic acid, Vitamins and minerals) with sales of HRK 74.8 m. recorded a much higher growth rate of 16.1%.

Fine Chemicals. The Fine Chemicals business segment increased sales by 46.2% over 1998 and totalled HRK 715.5 m., a rise of HRK 226.2 m. Almost all of the segment`s sales were realised on international markets, 99% originating from the US and Western European markets.
Azithromycin sales increased by 58.2% to HRK 599.5 m., once again the segment`s leading product. Over the course of 1999, azithromycin`s share of PLIVA Group sales jumped from 12.9% to 19%. The other four leading products also exhibited a strong growth of 23%.

Animal Health and Agrochemicals. Overall sales of Animal Health and Agrochemicals totalled HRK 190.8 m., HRK 8.4 m. or 4.2% less than 1998 figures.
Similarly, Croatian sales of HRK 125.5 m. represented a decline of HRK 5.4 m. or 3.5%, with respect to the previous year. This sales decrease is directly attributable to PLIVA`s
decision to introduce credit limits designed to limit supplies to defaulting customers, rather than artificially inflating sales.
International sales amounted to HRK 65.3 m., falling by HRK 3.8 m. or 5.5% against 1998. Irrespective of ambitious sales plans and intensified marketing activities on Eastern European markets, pre-set goals have not been met, largely as a result of setbacks in targeted economies.
Russian sales remained constant, while sales to B&H rose 38%.
Chinchilla Feedmix, which finds itself among the segment`s leading products, experienced a surge in growth of 136%. Furthermore, PLIVA`s policy of quality assurance enabled it to secure a lasting market position.

Foodstuffs. During 1999, the Foodstuffs segment realised sales of HRK 279.9 m., which is a 6.6% decrease in comparison to 1998.* Consolidating Trebipov sales of HRK 10 m., total foodstuffs sales would have resulted in a sales decrease of 3.1%.
Croatian sales amounted to HRK 210.8 m. (7.5% decrease), representing a 75.3% share of sales as opposed to 76.1% in 1998. The macroeconomic environment in 1999 was plagued by a low standard of living, persistent liquidity problems and a decrease in spending with respect to food products - with the exception of yeast, breakfast cereals and infant formula.
An upward sales growth trend continued on the major export markets of B&H and Slovenia, 4% and 15% respectively.
In 1999, the leading product Cedevita, a vitamin enriched instant beverage, retained the largest stake in foodstuffs sales, recording a total of HRK 118.5 m. The 21% increase on international markets softened the 11% decline in the product`s sales in Croatia.

Cosmetics and Personal Hygiene. The Cosmetics and Personal Hygiene segment, NEVA d.o.o., maintained 1998 sales levels at HRK 135.9 m. The sales level reflects the deteriorating economic environment both in Croatia (liquidity problems, reduced purchasing power and an drop in demand for cosmetics and personal hygiene products) and PLIVA`s export markets - B&H, Macedonia and Russia.
Similarly, increasingly fierce competition found on PLIVA`s export markets hindered the segment`s sales results.
Sales on the Croatian market brought in HRK 109.0 m., representing a 1.9% or HRK 2 m. increase over the preceding year. Thus, NEVA has retained its leading position on the cosmetics market with an 18% market share.
International sales experienced a decrease of 5.3% in 1999, constituting 19.8% of the
segment`s achieved sales. At 64.3% of sales and having experienced a growth of 8%, B&H further remains the segment`s most important export market. Sales on the Macedonian market, second to B&H, reached HRK 8.2 m., enjoying a significant 32% increase.
As the segment`s leading product, Plidenta toothpaste recorded significant sales of HRK 16.9 m.

[igor1]

Weitere infos? :http://www.pliva.hr/

[igor1]

Allianz erhöht Beteiligung an Zagrebacka banka auf zehn Prozent

Datum: 2000-07-06 Zeit: 10:06:09 WKN: 840400
Allianz erhöht Beteiligung an Zagrebacka banka auf zehn Prozent
Allianz erhöht Beteiligung an Zagrebacka banka auf zehn Prozent

München (vwd) - Die Allianz AG, München, hat ihre Beteiligung an der
Zagrebacka banka, Zagreb, auf zehn Prozent von derzeit sechs Prozent erhöht.
Dies teilte die Allianz am Donnerstag in München mit. Wie es weiter hieß,
planten beide Unternehmen, ihre bestehende Zusammenarbeit im
Versicherungsgeschäft auf die Bereiche Vermögensverwaltung und das neu
entstehende Pensionsfondsgeschäft auszuweiten. Die Allianz habe einen Sitz
im Aufsichtsrat der Zagrebacka banka übernommen.
(mehr/vwd/bst/sa)

[igor1]

Allianz erhöht Beteiligung an Zagrebacka banka ... (zwei)

Bereits im Juli 1998 hatte die Allianz die Versicherungsgesellschaft der
Zagrebacka banka übernommen und eine Kooperationsvereinbarung getroffen. Die
Bilanzsumme der Zagrebacka banka bezifferte die Allianz mit 3,3 Mrd EUR.
Nach Angaben der Allianz ist die Bank mit einem Drittel Marktanteil im
Privat- und Firmenkundengeschäft in Kroatien positioniert.

[igor1]

WKN Name 901576. ZAGREBACKA BANKA

[igor1]

ICH HABE FERTIG!

[zwrecht]

Hey Igor1:
Frage zu den 2 Perlen:
PLIVA DD GDR S 20/KK 100+Zagreb-Bank
-------------------------------------
Habe keine Ahnung von der derzeitigen politischen Lage.
Geht´s es in Kroatien/Jugoslawien einigermassen sicher
zu.
---
was würde passieren, wenn Milosevic u.Co (betrifft dies
überhaupt PLIVA u.Zagreb-Bank, regional gesehen
-habe wirklich keine Ahnung)wieder rankommen.
---
Oder handelt es sich bei PLIVA und ZAGREB um eine "relativ"
ruhige politische und geographische Lage.
=========
Bitte keine politischen Statements,
sondern nur DEINE persönliche Meinung.
Würdest, oder hast du von diesen beiden was gekauft ?

[igor1]

-dort in dieser Region war noch nie was gefährliches(seit ende 1995 in ganz Kroatien)

Croatia`s Average Money Market Rate Rises to 5.38 Percent Mon Oct 30 18:47:13 UTC+0100 2000
New Croatian Taxes May Hamper Investment Mon Oct 30 18:46:57 UTC+0100 2000
Croatian OTC Stocks Fall 1.73 Percent in Week to October 27 Mon Oct 30 11:30:27 UTC+0100 2000
Croatia`s Average Money Market Rate Eases to 3.38 Percent Fri Oct 27 18:07:48 UTC+0200 2000
Croatia Signs USD 14 Million Loan with World Bank Fri Oct 27 15:58:47 UTC+0200 2000
IMF Mission in Croatia for New Standby Deal Talks Thu Oct 26 19:33:39 UTC+0200 2000
Croatia Moves to Privatize Oil, Power Sectors Thu Oct 26 19:26:30 UTC+0200 2000
Zagreb Stocks Higher in Thin Trade on Pliva Thu Oct 26 16:48:29 UTC+0200 2000
Term Loans Lift Croatia Average Money Rate, Kuna Sinks Wed Oct 25 18:26:02 UTC+0200 2000
Croat Raiffeisenbank to Boost Capital in Growth Bid Tue Oct 24 18:16:39 UTC+0200 2000
Croatia`s Average Money Market Rate Rises to 3.54 Percent Tue Oct 24 18:16:13 UTC+0200 2000
Zagrebacka Slides to Drag Crobex 0.22 Percent Tue Oct 24 18:15:13 UTC+0200 2000
Croatian Podravka to Open Polish Plant Tue Oct 24 15:41:53 UTC+0200 2000
Zagreb Stocks Edge Higher in Thin Trade Mon Oct 23 18:49:13 UTC+0200 2000
Croatia`s Average Money Market Rate Falls to 3.07 Percent Mon Oct 23 18:48:45 UTC+0200 2000
Croatia OTC Stocks up, Rights Active in Week to October 20 Mon Oct 23 13:21:38 UTC+0200 2000
Croatia Ends Oil Blockade On Serbia Sat Oct 21 13:43:39 UTC+0200 2000
Zagrebacka Banka Lifts 1.61 Percent Fri Oct 20 19:11:13 UTC+0200 2000
Zagreb Stocks Close Firmer as Blue Chips Forge Ahead Thu Oct 19 18:38:48 UTC+0200 2000
Croatia Invites Hungary Firms for Hotel Sell-offs Thu Oct 19 16:32:29 UTC+0200 2000


http://www.croatia.net/resources/search.html

PLIVA _ STRONG BUY!

[igor1]

Lage dort sehr gut !

[igor1]

Zagrebacka banka d.d. has released its results for the first half of 2000
PLIVA d.d. has released its results for the first half of 2000

http://www.zse.hr/
THE ZAGREB STOCK EXCHANGE(ENGLISCH)

[zwrecht]

ZAGREB-Bank am 8.11.2000:
Hey Igor1
eine Deiner zwei Perlen wird zum Diamant !
----------------
über 15% Zuwachs !!!
-------
Land Name Börse WKN
Börse - + Kurs Diff. Diff. % Vol. Kurszeit

USA ZAGREBACKA BANKA D.... MUN 901576 21,00 B +2,80 +15,38% 76.770,00 16:22
USA ZAGREBACKA BANKA D.... ETR 901576 - +0,00 +0,00% - -
USA ZAGREBACKA BANKA D.... BER 901576 19,30 G +0,80 +4,32% - 19:46
USA ZAGREBACKA BANKA D.... FSE 901576 20,00 G +2,00 +11,11% - 16:18
USA PRZ.HANDLU ZAGR.UNI... ETR 907049 0,00 +0,00 +0,00% 0,00 18:29
USA PRZ.HANDLU ZAGR.UNI... BER 907049 0,62 +0,00 +0,00% - 09:32
USA PRZ.HANDLU ZAGR.UNI... FSE 907049 0,90 +0,00 +0,00% - 16:32
GREEN(DANIEL) CO NAS 4,50 -0,1875 -4,00% 18.000,00 19:11
AGREE REALTY NYS 14,00 +0,00 +0,00% 16.837,50 19:58

[zwrecht]

Hallo Igor1, wollte heute Zagreb-Bank kaufen (Kurs wie schon seit
Tagen bei 20 Euro); habe Kurslimit eingegeben 20; doch
keiner hatte was zu verkaufen. Na schaun wir mal morgen !

[igor1]

Berlin 21.00 n/a 16.11. 08:26 n/a n/a n/a n/a n/a [Detail]

Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.

[zwrecht]

Hallo igor1,
hab heute welche bekommen;
25 Stück zu 20,90 / mal schaun was die das nächste Jahr
machen (im Juli geb ich dir mal neue Nachricht !)

[igor1]

@ZWERCHT : PLIVA!



Berlin 12.60 13.00 17.11. 10:22 0.40 3.17% 13.00 13.00
Frankfurt 12.60 13.80 17.11. 14:10 1.20 9.52% 13.80 12.60

[igor1]

Meine empfelung am 29 .10 PLIVA bei 12.00E
Aktuel : 17 11. 13.80E

[Bär 3]

Wa